News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company’s Erbitux Fails In European Colon Cancer Study
October 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MILAN, Oct 10 (Reuters) - Two small European studies cast doubt on the benefits of two key bowel cancer drugs on Sunday, puzzling experts at Europe's biggest cancer meeting in Milan.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Eli Lilly and Company
MORE ON THIS TOPIC
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
March 30, 2026
·
2 min read
·
Annalee Armstrong
Immunology and Inflammation
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline
March 30, 2026
·
4 min read
·
Heather McKenzie
Cardiovascular disease
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure
March 30, 2026
·
2 min read
·
Tristan Manalac
Obesity
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
March 26, 2026
·
2 min read
·
Tristan Manalac
